Recent News
PPI Lawsuits: What’s Next?
The pharmaceutical liability attorneys at The Law Offices of Peter Angelos provide information regarding the risks related to proton pump inhibitors and the lawsuits filed by PPI consumers. Proton pump inhibitors (PPI) are used to treat a number of common abdominal conditions such as gastroesophageal reflux disease, stomach and duodenal ulcers, heartburn and erosive esophagitis….
Families Claim that Manufacturer Should Have Warned of Zofran Risks
The FDA approved Zofran, an antiemetic medication manufactured by GlaxoSmithKline (GSK) to prevent nausea and vomiting caused by cancer chemo therapy, radiation therapy, and surgery. Although Zofran was approved for distribution only for chemotherapy and radiation patients, GSK promoted the drug as an effective means to fight the same symptoms in pregnant women. Over the…
New Risk Associated with PPI Drugs
Proton pump inhibitors (PPIs) are a class of medication used to treat a number of common abdominal conditions such as gastroesophageal reflux disease, stomach and duodenal ulcers, heartburn and erosive esophagitis. Consumer brand PPIs include Nexium, Prevacid and Prilosec. Yet, a recent study, which includes data from nearly 200,000 patients treated through the Department of…
Blood Thinner Safety: What to Know When Taking Xarelto
Blood clots have the ability to prevent blood flow to patients’ organs such as the heart, lungs, and kidneys, potentially causing stroke and other life-threatening health conditions. There are many different medications on the market today that aim to reduce the risk of dangerous health conditions such as deep vein thrombosis, blood clot and stroke….
Studies Suggest Common Acid Reflux Medication Could Cause Severe Side Effects
Proton pump inhibitors (PPIs) are a class of medication used to treat a number of common abdominal conditions such as gastroesophageal reflux disease, stomach and duodenal ulcers, heartburn and erosive esophagitis. The medication works by obstructing the proton pump—an integral membrane protein—which then restricts or blocks the release of acid into a patient’s stomach. Common…
Recognizing the Dangerous Effects of Blood Thinners
Anticoagulants are a powerful way to prevent blood clots and stroke in atrial fibrillation patients, as these medications work by increasing blood flow within a patient’s body. However, these medications can also cause severe internal bleeding events which can lead to a number of serious and potentially fatal health complications. When prescribed an anticoagulant medication,…
Defective INR Device Used in Xarelto Clinical Trials
In February 2016, BMJ, a medical journal based in the United Kingdom, published a report detailing the use of a faulty device in the Xarelto clinical trials. The Alere international normalized ratio (INR) monitoring device was used to measure blood clotting in patients taking warfarin during the ROCKET-AF clinical trials. The report reveals that the…
FDA Provides Additional Warnings for SGLT2 Inhibitors
In May, the United States Food and Drug Administration released information advising physicians and patients to be cautious about the risks related to SGLT2 inhibitors. Now, the FDA has updated the warning label for the drugs to include the risk of ketoacidosis and severe urinary tract infection. SGLT2 inhibitors, like the drug Invokana, work to…
Xarelto Bellwether Trials to Begin in 2017
Dates have been selected for the first Xarelto multidistrict litigation hearings. Pretrial discovery and bellwether trial selection for the Xarelto multidistrict litigation (MDL) has begun. The first trials will consist of a selection of four cases, from a pool of forty, that have been considered to represent the majority of the cases filed around the…
FDA Increases Invokana Warnings
In September, the Food and Drug Administration (FDA) strengthened a warning that linked diabetes drug Invokana to an increased risk of bone fractures. The warning came as the result of various separate clinical studies showing that the medication reduced bone density in patients, and caused severe fractures. The FDA will continue to monitor Invokana and…